Expression of Multidrug Resistance-Associated P-Glycoprotein in Feline Tumours

被引:7
|
作者
Van der Heyden, S. [1 ]
Chiers, K. [1 ]
Vercauteren, G. [1 ]
Daminet, S. [2 ]
Wegge, B. [1 ]
Paepe, D. [2 ]
Ducatelle, R. [1 ]
机构
[1] Univ Ghent, Dept Pathol Bacteriol & Poultry Dis, B-9820 Merelbeke, Belgium
[2] Univ Ghent, Dept Small Anim Med & Clin Biol, Fac Vet Med, B-9820 Merelbeke, Belgium
关键词
cat; neoplasia; P-glycoprotein; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; CANINE LYMPHOMA; IMMUNOHISTOCHEMICAL DETECTION; MDR1; GENE; CANCER; MODULATION; PROTEIN; LIVER;
D O I
10.1016/j.jcpa.2010.08.008
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Permeability glycoprotein (P-gp) is a membrane-bound efflux pump that mediates the active transmembrane transport of a variety of substrates. Several studies in human and canine normal and neoplastic tissues indicate that P-gp is involved in resistance to chemotherapy and in the development of multidrug resistance (MDR). The purpose of this study was to evaluate P-gp expression with the monoclonal antibody C494 in common feline tumours from 88 patients not pretreated with chemotherapy. Tumours arising from tissues with intrinsic P-gp expression consistently showed positive labelling for P-gp in a cellular pattern identical to that described for the normal feline tissues. Both P-gp positive and negative tumour cells, however, were found in mammary gland tumours, lymphomas, mastocytomas and squamous cell carcinomas. Feline mammary gland tumours in particular showed strong membranous P-gp labelling, especially in areas with infiltrative growth and atypical cells, although this was not correlated with the grade of malignancy. These findings might have implications for future response to chemotherapy. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:164 / 169
页数:6
相关论文
共 50 条
  • [21] Schisandrin B: A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1
    Sun, Meng
    Xu, Xiaoli
    Lu, Qinghua
    Pan, Qiangrong
    Hu, Xun
    CANCER LETTERS, 2007, 246 (1-2) : 300 - 307
  • [22] 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
    NH Hendrikse
    EJF Franssen
    WTA van der Graaf
    C Meijer
    DA Piers
    W Vaalburg
    EGE de Vries
    British Journal of Cancer, 1998, 77 : 353 - 358
  • [23] 99mTc-sestamibi is a substrate for P-glycoprotein and the multidrug resistance-associated protein
    Hendrikse, NH
    Franssen, EJF
    van der Graaf, WTA
    Meijer, C
    Piers, DA
    Vaalburg, W
    de Vries, EGE
    BRITISH JOURNAL OF CANCER, 1998, 77 (03) : 353 - 358
  • [24] Tacrolimus is a P-glycoprotein but not a multidrug resistance-associated proteins or a concentrative nucleoside transporter 3 substrate
    Coste, G.
    Le Vee, M.
    Tron, C.
    Verdier, M. C.
    Fardel, O.
    Lemaitre, F.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2021, 35 : 95 - 95
  • [25] Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison
    Seelig, A
    Blatter, XL
    Wohnsland, F
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2000, 38 (03) : 111 - 121
  • [26] The multidrug resistance P-glycoprotein
    Higgins, Christopher F.
    CURRENT OPINION IN CELL BIOLOGY, 1993, 5 (04) : 684 - 687
  • [27] 8-PRENYLNARINGENIN INHIBITS BOTH P-GLYCOPROTEIN AND MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1
    Wesolowska, Olga
    Wisniewski, Jerzy
    Paprocka, Maria
    Dus, Danuta
    Michalak, Krystyna
    ANTICANCER RESEARCH, 2008, 28 (5C) : 3540 - 3541
  • [28] P-glycoprotein and multidrug resistance
    Johnston, JMN
    NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (20): : 1336 - 1336
  • [29] P-GLYCOPROTEIN AND MULTIDRUG RESISTANCE
    SKUBITZ, KM
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1990, 93 (01) : 156 - 157
  • [30] THE MULTIDRUG RESISTANCE P-GLYCOPROTEIN
    HIGGINS, CF
    PEDIATRIC PULMONOLOGY, 1992, : 100 - 100